Like the angiotensin II type 1 receptor blocker, endogenous estrogen (17␤-estradiol) is neuroprotective against cerebral ischemia; its effects are thought to be mediated by estrogen receptors (ERs). To verify the role of ERs and the brain renin-angiotensin system in estrogen-deficient rats with ischemia induced by middle cerebral artery occlusion, we compared rats subjected to oophorectomy (OVX ϩ ) with sham-oophorectomized rats (OVX Ϫ ) and OVX ϩ rats treated with 0.3 or 3.0 mg/kg of olmesartan for 2 weeks before middle cerebral artery occlusion. Independent of the blood pressure, the cortical infarct volume was larger in OVX ϩ than in OVX Ϫ rats. It was smaller in olmesartan-pretreated OVX ϩ rats. The expression of ER␣ in the peri-infarct region was correlated with the reduction of cortical infarct but not that of ER␤ or G protein-coupled estrogen receptor. Olmesartan prevented ER␣ downregulation in the cortical peri-infarct area, without affecting ER␤ or G protein-coupled estrogen receptor. Olmesartan also increased mRNA expression of angiotensin-converting enzyme 2, Bcl-2, and Bcl-xL and reduced angiotensin II and cleaved caspase 3. These effects were augmented by olmesartan and abolished by the ER inhibitor. In OVX ϩ rats treated with the ER␣ agonist alone, the infarct size was decreased, and the neuroprotective genes were upregulated. These findings suggest that the transactivation of neuroprotective genes and the reduction in brain angiotensin II are ER␣ dependent and that this may augment neuroprotection together with an angiotensin II type 1 receptor blockade by olmesartan. We present the new insight that the activation of ER␣ independent of estrogen contributes at least partly to limiting cerebral ischemic damage. (Hypertension. 2011;57:1161-1166.) • Online Data Supplement Key Words: cerebral ischemia Ⅲ estrogen receptor-␣, estrogen receptor-␤, G protein-coupled estrogen receptor Ⅲ brain renin-angiotensin system Ⅲ olmesartan Ⅲ oophorectomy
T he incidence of stroke is typically higher in middle-aged men than in women. Its increase in postmenopausal women is thought to be attributable to hypoestrogenicity. [1] [2] [3] The binding of estrogen to nuclear receptors, estrogen receptor (ER)-␣ and ER␤, can alter the protein expression involved in neuroprotection; both ER subtypes contribute to vasoprotection in a cell type-specific manner. [2] [3] [4] [5] [6] [7] [8] [9] [10] In addition to these "classic" ERs, the G protein-coupled ER (GPER) has been identified as a "nonclassic" receptor and shown to contribute to the rapid effects of estrogen. 10, 11 Although several studies examined the protective role of ERs against ischemic brain damage, 4, 5, 11, 12 the precise role of each ER remains obscure, especially under conditions of estrogen deficiency.
Activation of the renin-angiotensin system (RAS) predisposes to atherosclerosis and thromboembolic events and is involved in ischemic brain damage. 13 Angiotensin (Ang) II exerts blood vessel damaging actions; they are mediated mainly by the Ang II type 1 receptor (AT 1 R). The Ang II type 2 receptor (AT 2 R) is thought to counteract AT 1 R-mediated effects and to exert protective effects against ischemia. 14 Elsewhere we reported that, in male rats, the Ang II type 1 receptor blocker (ARB) exerts neuroprotective effects against cerebral ischemia; it upregulates endothelial NO synthase in an AT 2 R-dependent-and blood pressure-independent manner. 15 We also showed that the endothelial expression of AT 1 R and AT 2 R was modulated by estrogen and that the vasoprotective effects of ARB were augmented in the presence of estrogen. 16 However, there are few studies on the efficacy of ARB against cerebral ischemic damage and its mechanisms under estrogen-deficient conditions.
Renin converts angiotensinogen into Ang I, and Angconverting enzyme (ACE) converts Ang I into Ang II. ACE2, a homologue of ACE, converts mainly Ang II into the Ang-(1-7) peptide that binds to the Mas receptor to stimulate vasodilation and potentiate bradykinin; it thereby exerts cardioprotective effects. 17 Although the presence of ACE2 protein and mRNA in the mouse brain has been documented, 18, 19 variations in brain RAS components after cerebral ischemia under conditions of hypoestrogenicity remain to be elucidated.
We examined the role of ERs and assessed the effects of ARB and of RAS components under estrogen-deficient conditions in ischemic brain damage. We now present new evidence that ischemic brain damage, exaggerated in estrogen-deficient rats, is suppressed by ARB independent of the preischemic blood pressure and estrogen level and that its beneficial mechanism is partly associated with the upregulation of ER␣. This activation of ER␣ contributes to the upregulation of neuroprotective genes, resulting in the reduction of apoptosis in the peri-infarct area. We also demonstrate that ACE2 upregulation mediated by ER␣ reduces Ang II in the brain, thereby limiting the activation of the brain RAS after ischemia.
Materials and Methods
For a detailed description of Materials and Methods, see the online Data Supplement at http://hyper.ahajournals.org.
Results

The Cortical Infarct Volume, Increased in Estrogen-Deficient Rats Without Affecting the Blood Pressure, Was Reduced by Olmesartan
Before, during, and after middle cerebral artery occlusion (MCAO), the systolic, mean, and diastolic blood pressures were similar in oophorectomized (OVX ϩ /VC) and shamoophorectomized (OVX Ϫ /VC) rats serving as the vehicle controls (Table S1, available in the online Data Supplement at http://hyper.ahajournals.org). In OVX ϩ /VC rats, the cortical but not the basal ganglia infarct volume was significantly larger than in OVX Ϫ /VC rats (Figure 1 ), suggesting that estrogen deficiency by OVX blood pressure independently exacerbates the ischemic insult.
Before MCAO, the blood pressure in OVX ϩ rats treated with 0.3 but not with 3.0 mg/kg of olmesartan was similar to the blood pressure in OVX ϩ /VC rats. During and after MCAO it was lower in olmesartan-treated than OVX ϩ /VC rats (Table S1 ). The infarct volume in the cortex but not the basal ganglia was reduced in rats treated with 0.3 mg/kg (PϽ0.05) and 3.0 mg/kg (PϽ0.01; Figure 1 ). The reduction in the infarct volume in rats treated with 0.3 mg/kg of olmesartan appeared to be independent of their preischemic blood pressure. Because the cerebral blood flow was not different in any rats of all of the groups (data not shown), the suppression of a blood pressure increase during and after MCAO suggests that olmesartan improved cerebral blood flow autoregulation in OVX ϩ rats as it did in male rats. 15 
ER␣ Downregulation and RAS Activation After Brain Ischemia in OVX ؉ Rats Were Suppressed by Olmesartan
Based on the suggestion 20 that the presence of a penumbra may render therapeutic salvage possible, we focused on the role of ER and the brain RAS in the cortical peri-infarct area. Immunohistochemically, ER␣-positive neurons and endothelia ( Figure  S1A ) were increased in the ischemic penumbra of OVX Ϫ /VC rats ( Figure 2A ) compared with the nonischemic contralateral side (Figure S1B); this increase was lower in OVX ϩ /VC rats and enhanced by olmesartan treatment (Figure 2A and 2B). The mRNA level of ER␣ was correlated with protein expression ( Figure 3A ). On the other hand, the constitutive gene and protein expressions of ER␤ and GPER were detected on both sides of the brain and not affected by OVX and olmesartan (Figure S1C and S1D). Correlated with the reduced ER␣ expression, in OVX ϩ /VC rats the transcriptional activation of microtubuleassociated protein (MAP) 2, Bcl-2, and Bcl-xL as survival-and antiapoptosis-related genes was lower than in OVX Ϫ /VC rats ( Figure 3B through 3D). The expression of cleaved caspase 3 was increased in OVX ϩ /VC rats (Figure 2A On the other hand, the protein expression of Ang II and AT 1 R was higher in OVX ϩ /VC than OVX Ϫ /VC rats (Figure 2A , 2D, and 2E); the expression of AT 2 R was lower in OVX ϩ /VC rats (Figure 2A and 2F). Their expression was mainly observed in neurons and endothelial cells of the penumbra after MCAO ( Figure S2A through S2C). The mRNA level of AT 1 R and AT 2 R was correlated with their protein expression ( Figure 3E and 3F). In OVX ϩ /VC rats, ACE2 mRNA but not ACE mRNA was decreased ( Figure 3G and 3H). Olmesartan also restored these phenomena in OVX ϩ /VC rats (Figures 2A and 2D through 2F and 3E, 3F, and 3H). These results suggest that estrogen deficiency induced by OVX downregulated ER␣ and promoted the increase in Ang II and AT 1 R expression. Olmesartan may limit the infarct size through the upregulation of ER␣ and of the neuroprotective molecules and by inhibiting brain RAS activation.
Neuroprotection by Olmesartan Was Partly Dependent on ER␣
To further confirm that the activation of ER␣ in the estrogendeficient state is associated with the induction of neuropro- tective molecules, we administered ER inhibitor (ERI) ICI 182 780 to rats treated with 3.0 mg/kg of olmesartan. ERI partially abolished the olmesartan-induced reduction in the infarct volume ( Figure 4A ). The olmesartan-induced increase in ACE2 mRNA was reversed by ERI ( Figure 4E ). However, neither the olmesartan-induced downregulation of AT 1 R nor the upregulation of AT 2 R was affected by ERI ( Figure S3A and S3B). ERI treatment increased the expression of Ang II ( Figure 4B ), indicating that the upregulation of ACE2 by olmesartan is mediated by ER␣, resulting in the reduction of brain Ang II expression. The expression of cleaved caspase 3 was increased by ERI ( Figure 4C ); the olmesartan-induced elevation in the mRNA level of Bcl-2 and Bcl-xL but not of MAP2 was abrogated by ERI ( Figures 4F, 4G, and S3C ). The serine 118 residue (Ser-118) in ER␣ is a major site of phosphorylation in response to its ligand. Phosphorylated ER␣ influences the recruitment of coactivators of transcription. 21 The expression of phosphorylated and total ER␣ was increased by olmesartan and decreased by ERI ( Figure 4D ), suggesting that the transcriptional activation of antiapoptotic genes is associated with the olmesartan-induced upregulation of phosphorylated ER␣.
To further confirm the functional role of ER␣ on neuroprotection after ischemia, we treated OVX ϩ /VC rats with the ER␣ agonist propyl pyrazole triol. The infarct volume was reduced, and the mRNA level of ACE2, Bcl-2, and Bcl-xL was upregulated in the peri-infarct area of propyl pyrazole triol-treated compared with nontreated rats ( Figure 5A through 5D ), suggesting an essential role of ER␣ activation after ischemia.
Discussion
We present new insights into neuroprotection after cerebral ischemia in OVX ϩ rats. First, we demonstrated that estrogen deficiency exaggerated ischemic brain damage and that ER␣ activation was associated with neuroprotection against ischemic damage independent of estrogen. Olmesartan augmented the activation of ER␣ and suppressed brain damage in OVX ϩ rats independent of the preischemic blood pressure. Second, we found that the activation of ER␣ induced the transcriptional activation of antiapoptotic Bcl-2 and Bcl-xL, resulting in the reduction of cleaved caspase 3. More importantly, it upregulated ACE2 and reduced Ang II; the upregulation of ACE2 and antiapoptotic molecules was ER␣ dependent, whereas the regulation of AT 1 R, AT 2 R, and MAP2 was not. These findings suggest that ER␣ activation is essential for and contributes at least partly to neuroprotection after ischemia under estrogendeficient conditions and that olmesartan has ER␣-dependent and -independent effects in addition to the blockade of AT 1 R. ER␣ is essential in estradiol-mediated protection against cell death in the brain. 4, 5 We showed that, under estrogendeficient conditions, the olmesartan-induced upregulation of ER␣ was associated with the upregulation of antiapoptotic genes, resulting in a reduction in the cortical infarct size. Previous reports demonstrated ER␤-dependent neuroprotection after ischemia 12 and that GPER activation was associated with acute vasoprotective and neuroprotective effects. 10 Other studies showed that ER␤ was irrelevant to neuroprotection and that GPER led to enhanced apoptosis via extracellular signal-regulated kinase activation. 5, 22 Because we found that neither estrogen nor olmesartan had an effect on the protein and mRNA expression of ER␤ and GPER, we cannot state that ER␤ and GPER protect against ischemic damage.
Several specific mechanisms are involved in the modulation of ER␣ expression. 4, 23, 24 In female rats, ischemia led to demethylation of the ER␣ promoter, resulting in an increase in the expression of ER␣. 4 The expression of ER␣ on ischemia was enhanced by olmesartan even in OVX ϩ rats. The stabilization of ER␣ or the promotion of its demethylation by olmesartan may be related to the increase in ER␣ under estrogen-deficient and ischemic conditions. Additional studies are necessary to elucidate more details on the regulation of ER␣ expression.
ER␣ contains the N-terminal ligand-independent activation function (AF1)-, the DNA binding-, the hinge-, and the C-terminal ligand binding domain that contain a ligandregulated activation function (AF2). 21, 25 In response to estrogen, AF1 synergizes with AF2. Thus, AF1 plays a role in both ligand-dependent and -independent transcription. In addition, Ser-118 in ER␣ is located within the AF1 region and is phosphorylated in response to the activation of cellular kinases by extracellular signals. 21 The olmesartan-induced elevation of phosphorylated ER␣ would be involved in the transcriptional activation of neuroprotective genes via a ligand-independent pathway associated with AF1.
In animals treated with ARB, ACE2 expression was increased in the heart and kidney. 18 We first observed that, in OVX ϩ rats treated with olmesartan, the transcriptional activity of ACE2 was increased through the activation of ER␣ in the cerebral ischemic penumbra. The upregulation of ACE2 via ER␣ activation by olmesartan may reduce Ang II expression and thereby contribute at least partly to limiting brain damage after ischemia.
Compared with OVX ϩ rats, the expression of AT 1 R was decreased and the expression of AT 2 R was increased in OVX Ϫ rats; these were similar to the effects elicited by olmesartan. These data suggest that neuroprotection by not only olmesartan but also by endogenous estrogen may be associated with both AT 1 R and AT 2 R expression. This result is partially consistent with an earlier report. 16, 26 However, Figure 5 . Effects of the estrogen receptor (ER)␣ agonist propyl pyrazole triol (PPT) on cerebral ischemia in OVX ϩ rats. We treated OVX ϩ /VC rats with the ER␣ agonist PPT (2.0 mg/kg). In rats treated with PPT, the infarct volume was reduced (A), and the mRNA level of ACE2 (B), Bcl-2 (C), and Bcl-xL (D) was upregulated in the peri-infarct area compared with nontreated rats (each group nϭ8). Each bar represents the meanϮSD. *PϽ0.05 vs OVX ϩ /VC by ANOVA followed by the Mann-Whitney U test. ACE2 indicates angiotensinconverting enzyme 2; olm, olmesartan; MCAO, middle cerebral artery occlusion; OVX, oophorectomy; VC, vehicle control.
Perspectives
We first demonstrate the regulation of ER␣ by ARB in vivo. Additional studies are underway to clarify whether ER␣ contributes to neuroprotection in male rats. Ovariectomized animals 28 -30 mimicking the status of postmenopausal women may serve as a model of "surgical menopause," a condition associated with the development of accelerated atherosclerosis and hypertension in humans. Because we used 13-week-old normotensive rats manifesting hypoestrogenicity for 4 weeks, our results may not reflect the possible effects of aging, hypertension, and prolonged ovarian hormone deprivation.
Although we cannot rule out other mechanisms underlying the neuroprotection by olmesartan, it may represent a therapeutic means for treating cerebrovascular damage in menopausal and cycling women. In clinical studies, important questions have been raised regarding the effects of estrogen on vascular inflammation. To demonstrate the benefits of olmesartan as an alternative to hormone replacement therapy and to elucidate its neuroprotective role in postmenopausal women, prudent clinical studies are needed.
